ASPIRE-HR is a Phase 3 clinical trial evaluating oral ibuzatrelvir in non-hospitalized, symptomatic adult (18+) and adolescent (12+) participants with COVID-19 who are at high risk of progressing to severe illness due to underlying risk factors.

These risk factors include:

• BMI ≥30 kg/m²
• Current smoker
• Chronic lung disease
• Asthma requiring daily prescribed therapy
• Cardiovascular disease
• Type 1 or Type 2 diabetes
• Mild to moderate renal impairment
• Neurodevelopmental disorders
• Sickle cell disease
• Moderate immunosuppression

Additional requirements apply.

ASPIRE-IC is a Phase 3 clinical trial evaluating oral ibuzatrelvir in adults (18+) with symptomatic COVID-19 who are severely immunocompromised.

This clinical trial is enrolling patients who are immunocompromised due to:

• Solid organ or islet cell transplant recipient who is receiving immunosuppressive therapy
• Active hematologic malignancy (e.g., chronic lymphocytic lymphoma, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)
• Receipt of CAR-T cell therapy or HCT either within 2 years of transplantation or who are receiving immunosuppressive therapy
• Currently receiving B-cell depleting therapies (e.g., rituximab, ocrelizumab, ofatumumab, epratuzmab)

Additional requirements apply.